NZ599151A - Pharmaceutical composition comprising radezolid or salt thereof and uses thereof - Google Patents

Pharmaceutical composition comprising radezolid or salt thereof and uses thereof

Info

Publication number
NZ599151A
NZ599151A NZ599151A NZ59915110A NZ599151A NZ 599151 A NZ599151 A NZ 599151A NZ 599151 A NZ599151 A NZ 599151A NZ 59915110 A NZ59915110 A NZ 59915110A NZ 599151 A NZ599151 A NZ 599151A
Authority
NZ
New Zealand
Prior art keywords
radezolid
salt
pharmaceutical composition
disclosed
composition
Prior art date
Application number
NZ599151A
Other languages
English (en)
Inventor
Eric S Burak
Danping Li
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of NZ599151A publication Critical patent/NZ599151A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ599151A 2009-10-13 2010-10-12 Pharmaceutical composition comprising radezolid or salt thereof and uses thereof NZ599151A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25102309P 2009-10-13 2009-10-13
PCT/US2010/052263 WO2011046905A2 (en) 2009-10-13 2010-10-12 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
NZ599151A true NZ599151A (en) 2014-07-25

Family

ID=43876821

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ599151A NZ599151A (en) 2009-10-13 2010-10-12 Pharmaceutical composition comprising radezolid or salt thereof and uses thereof

Country Status (16)

Country Link
US (2) US20120208857A1 (enExample)
EP (2) EP2488175A4 (enExample)
JP (3) JP2013507443A (enExample)
KR (1) KR101791709B1 (enExample)
CN (1) CN102573840A (enExample)
AU (2) AU2010307054A1 (enExample)
BR (1) BR112012008649A2 (enExample)
CA (1) CA2776310A1 (enExample)
EA (1) EA022765B1 (enExample)
IL (1) IL219018A (enExample)
MX (1) MX337145B (enExample)
NZ (1) NZ599151A (enExample)
PH (1) PH12012500695A1 (enExample)
SG (1) SG10201406571YA (enExample)
UA (1) UA111145C2 (enExample)
WO (1) WO2011046905A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA027791B1 (ru) 2010-11-24 2017-09-29 Мелинта Терапьютикс, Инк. Фармацевтические композиции
CN104784113B (zh) * 2015-04-30 2017-09-29 成都国为生物医药有限公司 一种含有利奈唑胺的组合物及其制备方法
US11112370B2 (en) * 2019-01-04 2021-09-07 The Boeing Company Reconfigurable backscatter detector

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688792A (en) * 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
MY127336A (en) * 2000-03-22 2006-11-30 Upjohn Co Container for linezolid iv solution
PE20011088A1 (es) * 2000-03-22 2001-10-04 Upjohn Co Tratamiento de infecciones del tracto urinario con oxazolidinonas antibacterianas
NZ522990A (en) 2000-06-05 2003-08-29 Dong A Pharm Novel oxazolidinone derivatives and a process for the preparation thereof
MY137618A (en) * 2000-08-22 2009-02-27 Pharmacia Corp Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading
US6696426B2 (en) * 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
TWI378092B (en) 2003-06-03 2012-12-01 Rib X Pharmaceuticals Inc Biaryl heterocyclic compounds and methods of making and using the same
US20060270680A1 (en) * 2003-06-03 2006-11-30 Goldberg Joel A Sulfonamide compounds and methods of making and using the same
JP2007514782A (ja) 2003-12-17 2007-06-07 リブ−エックス ファーマシューティカルズ,インコーポレイテッド ハロゲン化ビアリール複素環式化合物ならびにその作製方法および使用方法
KR100854211B1 (ko) * 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US7696211B2 (en) * 2005-04-29 2010-04-13 Wilson Constance N Methods and pharmaceutical compositions for treating sepsis
US20070249577A1 (en) * 2005-05-10 2007-10-25 Hopkins Scott J Method for reducing the risk of or preventing infection due to surgical or invasive medical procedures
WO2007086011A1 (en) * 2006-01-25 2007-08-02 Jegannathan Srinivas Formulation comprising cefepime, tazobactam and linezolid
WO2007133803A2 (en) * 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2008085913A1 (en) 2007-01-04 2008-07-17 Rib-X Pharmaceuticals, Inc. Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections

Also Published As

Publication number Publication date
EP3095445A1 (en) 2016-11-23
PH12012500695A1 (en) 2024-02-12
MX2012004282A (es) 2012-05-22
KR101791709B1 (ko) 2017-10-30
CN102573840A (zh) 2012-07-11
SG10201406571YA (en) 2014-11-27
EA022765B1 (ru) 2016-02-29
KR20120099676A (ko) 2012-09-11
EP2488175A2 (en) 2012-08-22
WO2011046905A3 (en) 2011-10-20
WO2011046905A2 (en) 2011-04-21
EP2488175A4 (en) 2013-08-07
EA201270547A1 (ru) 2012-12-28
IL219018A (en) 2016-11-30
US20120208857A1 (en) 2012-08-16
JP2017141285A (ja) 2017-08-17
AU2010307054A1 (en) 2012-04-26
US20150165040A1 (en) 2015-06-18
MX337145B (es) 2016-02-15
JP2013507443A (ja) 2013-03-04
CA2776310A1 (en) 2011-04-21
UA111145C2 (uk) 2016-04-11
AU2016234893A1 (en) 2016-10-20
BR112012008649A2 (pt) 2021-11-03
JP2015155479A (ja) 2015-08-27
IL219018A0 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
UA90048C2 (ru) Кондиционированная композиция и способ ее получения
NZ597237A (en) Sublingual apomorphine
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MY166789A (en) Arginine salts and their uses for the treatment of illnesses in the oral cavity
PH12014501213A1 (en) Aqueous oral care compositions
MX2009005413A (es) Formas cristalinas del acido zoledronico.
PH12013500223A1 (en) Oral care product and methods of use and manufacture thereof
ZA200906233B (en) Compositions and methods to control the growth of micro-organisms in aqueous systems
WO2011153460A3 (en) Therapeutic amoeba and uses thereof
CL2012003168A1 (es) Composicion farmaceutica que comprende una solucion acuosa de minociclina y un cation divalente o trivalente en una proporcion mayor de 2:1 con respecto a la minociclina; metodo de preparacion; kit y uso en el tratamiento de infecciones bacterianas.
UA107204C2 (uk) Протигрибкова композиція, що містить грибковий організм pythium oligandrum
MX2009007384A (es) Formulaciones que contienen ?-lactama con elevada estabilidad en disolucion acuosa.
DOP2011000245A (es) Derivados de tiadiazoles y oxadiazoles, su preparacion y su aplicacion en terapeutica
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
UA109269C2 (uk) Незлежувана композиція хлориду калію, спосіб її отримання і застосування
ZA201008160B (en) Compositions for the treatment of hair loss
GEP20135892B (en) Nifuratel application at infection treatment caused by atopobium
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
PH12020550222A1 (en) Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections
RU2011134979A (ru) Композиция для снижения жесткости воды
UA111145C2 (uk) Фармацевтична композиція
ATE524488T1 (de) Lysobactinamide
NO20073757L (no) Topiske vaginale farmasoytiske sammensetninger
MX2012003734A (es) Composicones de dibromomalonamida y su uso como biocidas.
PH12013501523A1 (en) Use of nifuratel to treat infections caused by clostridium species

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 12 OCT 2017 BY CULLENS

Effective date: 20141231

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2018 BY COMPUTER PACKAGES INC

Effective date: 20170920

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 12 OCT 2019 BY COMPUTER PACKAGES INC

Effective date: 20181002

LAPS Patent lapsed